The Indian pharmaceutical market saw a 9% increase in value in February, with key pharmaceutical sectors showing positive growth trends.
Anti-cancer systems, disease prevention, and cancer drivers, according to research firm PharmaTrac. We have seen volume growth for a month. However, the respiratory segment has slowed since the winter harvest, with unit growth to 11.7% in February 2024.
Sheetal Sapale, Commercial Vice President, PharmaTrack, said, “New product launches and pricing strategies contributed to good growth in February, although volume growth was modest."
The Indian pharmaceutical market showed modest growth of 0.2% in February, which was strong in all medical fields. USV Glycomet GP maintained its position as the most popular pharmaceutical brand. Augmentin achieved 77 million rupees in February, taking its total sales from February 2023 to February 2024 to 822 million. Meanwhile, Glycomet GP posted revenue of Rs 66 crore in February 2024 and Rs 785 crore in February 2023.
, CDSCO.jpg)
.jpg)